Impact of cytochrome P450 2C19 polymorphisms on the pharmacokinetics of tacrolimus when coadministered with voriconazole

Chiyo Imamura, Kenichi Furihata, Shinichiro Okamoto, Yusuke Tanigawara

Research output: Contribution to journalArticle

17 Citations (Scopus)

Abstract

This study evaluated the effects of cytochrome P450 (CYP) 2C19 polymorphisms on tacrolimus pharmacokinetics when coadministered with voriconazole. Eighteen healthy volunteers, including 6 individuals in each CYP2C19 genotype (extensive metabolizers [EMs], intermediate metabolizers [IMs], and poor metabolizers [PMs]), received a single oral dose of 3 mg tacrolimus alone or in combination with 200 mg voriconazole twice daily at steady state. When tacrolimus was coadministered with voriconazole, a significant increase in area under its concentration-time curve (AUC0-24) was observed for all genotypes. AUC0-12 of voriconazole in IMs and PMs were significantly higher than that in EMs (P 0-24 of tacrolimus in combination with voriconazole in IMs and PMs were also significantly higher than that in EMs (P

Original languageEnglish
Pages (from-to)408-413
Number of pages6
JournalJournal of Clinical Pharmacology
Volume56
Issue number4
DOIs
Publication statusPublished - 2016 Apr 1

Fingerprint

Tacrolimus
Cytochrome P-450 Enzyme System
Pharmacokinetics
Genotype
Healthy Volunteers
Voriconazole

Keywords

  • CYP2C19 polymorphism
  • CYP3A
  • drug interaction
  • tacrolimus
  • voriconazole

ASJC Scopus subject areas

  • Pharmacology (medical)
  • Pharmacology

Cite this

Impact of cytochrome P450 2C19 polymorphisms on the pharmacokinetics of tacrolimus when coadministered with voriconazole. / Imamura, Chiyo; Furihata, Kenichi; Okamoto, Shinichiro; Tanigawara, Yusuke.

In: Journal of Clinical Pharmacology, Vol. 56, No. 4, 01.04.2016, p. 408-413.

Research output: Contribution to journalArticle

@article{790065243cc64a46a4abc902108eea6a,
title = "Impact of cytochrome P450 2C19 polymorphisms on the pharmacokinetics of tacrolimus when coadministered with voriconazole",
abstract = "This study evaluated the effects of cytochrome P450 (CYP) 2C19 polymorphisms on tacrolimus pharmacokinetics when coadministered with voriconazole. Eighteen healthy volunteers, including 6 individuals in each CYP2C19 genotype (extensive metabolizers [EMs], intermediate metabolizers [IMs], and poor metabolizers [PMs]), received a single oral dose of 3 mg tacrolimus alone or in combination with 200 mg voriconazole twice daily at steady state. When tacrolimus was coadministered with voriconazole, a significant increase in area under its concentration-time curve (AUC0-24) was observed for all genotypes. AUC0-12 of voriconazole in IMs and PMs were significantly higher than that in EMs (P 0-24 of tacrolimus in combination with voriconazole in IMs and PMs were also significantly higher than that in EMs (P",
keywords = "CYP2C19 polymorphism, CYP3A, drug interaction, tacrolimus, voriconazole",
author = "Chiyo Imamura and Kenichi Furihata and Shinichiro Okamoto and Yusuke Tanigawara",
year = "2016",
month = "4",
day = "1",
doi = "10.1002/jcph.605",
language = "English",
volume = "56",
pages = "408--413",
journal = "Journal of Clinical Pharmacology",
issn = "0091-2700",
publisher = "SAGE Publications Inc.",
number = "4",

}

TY - JOUR

T1 - Impact of cytochrome P450 2C19 polymorphisms on the pharmacokinetics of tacrolimus when coadministered with voriconazole

AU - Imamura, Chiyo

AU - Furihata, Kenichi

AU - Okamoto, Shinichiro

AU - Tanigawara, Yusuke

PY - 2016/4/1

Y1 - 2016/4/1

N2 - This study evaluated the effects of cytochrome P450 (CYP) 2C19 polymorphisms on tacrolimus pharmacokinetics when coadministered with voriconazole. Eighteen healthy volunteers, including 6 individuals in each CYP2C19 genotype (extensive metabolizers [EMs], intermediate metabolizers [IMs], and poor metabolizers [PMs]), received a single oral dose of 3 mg tacrolimus alone or in combination with 200 mg voriconazole twice daily at steady state. When tacrolimus was coadministered with voriconazole, a significant increase in area under its concentration-time curve (AUC0-24) was observed for all genotypes. AUC0-12 of voriconazole in IMs and PMs were significantly higher than that in EMs (P 0-24 of tacrolimus in combination with voriconazole in IMs and PMs were also significantly higher than that in EMs (P

AB - This study evaluated the effects of cytochrome P450 (CYP) 2C19 polymorphisms on tacrolimus pharmacokinetics when coadministered with voriconazole. Eighteen healthy volunteers, including 6 individuals in each CYP2C19 genotype (extensive metabolizers [EMs], intermediate metabolizers [IMs], and poor metabolizers [PMs]), received a single oral dose of 3 mg tacrolimus alone or in combination with 200 mg voriconazole twice daily at steady state. When tacrolimus was coadministered with voriconazole, a significant increase in area under its concentration-time curve (AUC0-24) was observed for all genotypes. AUC0-12 of voriconazole in IMs and PMs were significantly higher than that in EMs (P 0-24 of tacrolimus in combination with voriconazole in IMs and PMs were also significantly higher than that in EMs (P

KW - CYP2C19 polymorphism

KW - CYP3A

KW - drug interaction

KW - tacrolimus

KW - voriconazole

UR - http://www.scopus.com/inward/record.url?scp=84960100931&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84960100931&partnerID=8YFLogxK

U2 - 10.1002/jcph.605

DO - 10.1002/jcph.605

M3 - Article

C2 - 26239045

AN - SCOPUS:84960100931

VL - 56

SP - 408

EP - 413

JO - Journal of Clinical Pharmacology

JF - Journal of Clinical Pharmacology

SN - 0091-2700

IS - 4

ER -